View in EDS

Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.

Saved in:
Bibliographic Details
Title: Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation.
Authors: Smith JM; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barlaam B; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Bradshaw L; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Chan HM; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Cooke SL; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cronin A; Oncology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cumming I; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Dean E; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Debreczeni JÉ; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barco Barrantes ID; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ferguson D; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Gianni D; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Grondine M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Lynch JT; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., McWilliams L; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Moore S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Raubo P; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Qu Y; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China., Robb GR; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Tan L; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China., Urosevic J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vazquez-Chantada M; Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Wang P; Pharmaron Beijing Co., Ltd, Beijing 100176, P. R. China.
Source: Journal of medicinal chemistry [J Med Chem] 2026 Jun 11; Vol. 69 (11), pp. 13725-13752. Date of Electronic Publication: 2026 May 22.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.6c00659